Eton Pharmaceuticals, Inc. (ETON) stock
ETONNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 10/30521% above fair value
$63.65−0.23 (-0.36%)
Close on Nov 17, 2026Market cap $1.82BP/E 163.2Yield –
Eton Pharmaceuticals total debt
Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.
Eton Pharmaceuticals's total debt was $27.90M at Jun 30, 2026. For fiscal 2025 it was $30.56M, up 2.5% from the year before. The highest annual figure on record is $30.56M in fiscal 2025.
Annual total debt
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $30.56M | +2.5% |
| FY2024 | Dec 31, 2024 | $29.81M | +454.1% |
| FY2023 | Dec 31, 2023 | $5.38M | +420.8% |
| FY2022 | Dec 31, 2022 | $1.03M | -27.2% |
| FY2021 | Dec 31, 2021 | $1.42M | – |
Quarterly total debt
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $27.90M | -7.5% |
| Q1 FY2026 | Mar 31, 2026 | $30.75M | +3.1% |
| Q4 FY2025 | Dec 31, 2025 | $30.56M | +640.8% |
| Q3 FY2025 | Sep 30, 2025 | $30.37M | +551.9% |
| Q2 FY2025 | Jun 30, 2025 | $30.18M | +501.2% |
| Q4 FY2024 | Dec 31, 2024 | $29.81M | +454.1% |
| Q3 FY2024 | Sep 30, 2024 | $4.13M | +167.9% |
| Q2 FY2024 | Jun 30, 2024 | $4.66M | +202.5% |
| Q1 FY2024 | Mar 31, 2024 | $5.02M | +274.9% |
| Q4 FY2023 | Dec 31, 2023 | $5.38M | +420.8% |
| Q3 FY2023 | Sep 30, 2023 | $1.54M | +117.5% |
| Q2 FY2023 | Jun 30, 2023 | $1.54M | +323.1% |
| Q1 FY2023 | Mar 31, 2023 | $1.34M | -5.6% |
| Q4 FY2022 | Dec 31, 2022 | $1.03M | -5.4% |
| Q3 FY2022 | Sep 30, 2022 | $708.00K | -5.5% |
| Q2 FY2022 | Jun 30, 2022 | $364.00K | -5.5% |
| Q4 FY2021 | Dec 31, 2021 | $1.42M | – |
| Q3 FY2021 | Sep 30, 2021 | $1.09M | – |
| Q2 FY2021 | Jun 30, 2021 | $749.00K | – |
| Q1 FY2021 | Mar 31, 2021 | $385.00K | – |
See a number that looks wrong?